Il-23r antagonists to reprogram intratumoral t regulatory cells into effector cells
AssigneeDana-Farber Cancer Institute, Inc.
InventorsHarvey Cantor, Hye-Jung Kim, Jessica M. Sido
Life of this patent
Estimating the term…
Abstract
Provided by the disclosure are compositions and methods for modulating differentiation of regulatory T cells. In some embodiments, methods include selectively decreasing IL-23R activity and/or IL-23R expression without significantly decreasing IL-12RP activity and/or IL-12RP expression.
Claims19
1-31. (canceled)
A method for treating cancer in a human subject, the method comprising:
- administering to the human subject an agent that decreases IL-23R and does not decrease IL-12Rβ activity, in an amount effective to treat the cancer.
A method for inducing differentiation of a regulatory T (Treg) cell to an effector T cell (Teff), comprising contacting the Treg cell with an agent that decreases IL-23R activity and does not decrease IL-12Rβ activity.
Dependencies are inferred from the claim text.